tiprankstipranks
Jinhai International Group Holdings Limited (HK:2225)
:2225
Hong Kong Market
Want to see HK:2225 full AI Analyst Report?

Jinhai International Group Holdings Limited (2225) AI Stock Analysis

1 Followers

Top Page

HK:2225

Jinhai International Group Holdings Limited

(2225)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - Gpt-5.6Sol)
Rating:54Neutral
Price Target:
HK$6.50
▲(424.19% Upside)
Action:Reiterated
Date:09/10/26
The score is held down primarily by weak financial performance (sharp margin compression, large losses, and negative operating/free cash flow over 2023–2025) and a loss-driven negative P/E. This is partially offset by strong technical momentum, with the stock trading well above key moving averages and a positive MACD.
Positive Factors
Recent Revenue Growth
Revenue growth in 2025 indicates the company continued expanding its top line despite broader profitability pressure. If maintained, this can support greater operating scale, improve the revenue base available to absorb fixed costs, and provide a platform for future margin recovery.
Negative Factors
Severe Margin Compression
The sharp, multi-year decline in gross margin signals substantial deterioration in the economics of the business. Lower gross profitability leaves less revenue available to cover operating costs, making earnings recovery harder and suggesting that pricing pressure or cost control issues may persist over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recent Revenue Growth
Revenue growth in 2025 indicates the company continued expanding its top line despite broader profitability pressure. If maintained, this can support greater operating scale, improve the revenue base available to absorb fixed costs, and provide a platform for future margin recovery.
Read all positive factors

Jinhai International Group Holdings Limited (2225) vs. iShares MSCI Hong Kong ETF (EWH)

Jinhai International Group Holdings Limited Business Overview & Revenue Model

Company Description
Jinhai Medical Technology Ltd. specializes in offering workforce solutions and a range of complementary support services. Catering primarily to building and construction contractors, their comprehensive service portfolio encompasses dormitory mana...

Jinhai International Group Holdings Limited Financial Statement Overview

Summary
Despite revenue growth in 2025 (+17.5%), profitability and cash generation are very weak: gross margin has fallen sharply, net margin is deeply negative (~-36.9%), and operating/free cash flow have been negative for three straight years (2023–2025). The balance sheet leverage is manageable (debt-to-equity <0.5), but persistently negative ROE and ongoing losses keep the overall financial profile pressured.
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue66.07M46.28M50.24M45.64M22.28M21.90M
Gross Profit11.79M7.19M11.48M12.03M10.12M7.73M
EBITDA-6.72M-14.39M-16.82M1.11M5.25M5.44M
Net Income-11.23M-17.08M-17.96M-3.14M468.00K-246.21K
Balance Sheet
Total Assets100.24M88.83M58.87M62.22M40.27M33.77M
Cash, Cash Equivalents and Short-Term Investments29.25M36.78M14.93M26.76M23.95M25.91M
Total Debt14.20M14.91M14.52M10.08M4.45M1.87M
Total Liabilities44.58M36.87M26.09M24.73M15.68M9.75M
Stockholders Equity51.91M51.28M31.81M37.47M24.37M24.28M
Cash Flow
Free Cash Flow2.54M-6.18M-4.26M-3.15M3.06M2.73M
Operating Cash Flow2.61M-6.08M-3.25M-1.91M4.24M3.34M
Investing Cash Flow956.46K3.47M-9.22M-6.51M-1.15M-2.64M
Financing Cash Flow26.76M26.68M2.93M13.62M-3.72M-4.81M

Jinhai International Group Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.24
Price Trends
50DMA
4.35
Positive
100DMA
4.09
Positive
200DMA
2.91
Positive
Market Momentum
MACD
0.26
Negative
RSI
68.72
Neutral
STOCH
73.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2225, the sentiment is Positive. The current price of 1.24 is below the 20-day moving average (MA) of 5.08, below the 50-day MA of 4.35, and below the 200-day MA of 2.91, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 68.72 is Neutral, neither overbought nor oversold. The STOCH value of 73.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2225.

Jinhai International Group Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
HK$1.03B5.4015.17%35.98%6.09%21.21%
65
Neutral
HK$1.24B8.563.86%8.26%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
54
Neutral
HK$30.36B-496.85-21.76%75.36%49.21%
54
Neutral
HK$553.37M4.178.42%5.41%9.13%
44
Neutral
HK$108.20M-3.36-43.31%29.46%
42
Neutral
HK$45.00M-20.14-1.28%-14.98%-120.83%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2225
Jinhai International Group Holdings Limited
6.48
5.55
596.24%
HK:2180
ManpowerGroup Greater China Limited
4.92
-0.65
-11.67%
HK:6100
Tongdao Liepin Group
2.42
-1.07
-30.70%
HK:6919
Renrui Human Resources Technology Holdings Limited
3.51
-1.13
-24.35%
HK:8031
ETS Group Limited
0.28
0.16
133.33%
HK:8462
Omnibridge Holdings Ltd.
0.08
>-0.01
-8.54%

Jinhai International Group Holdings Limited Corporate Events

Jinhai Medical Narrows Interim Loss as Revenue More Than Doubles
Aug 27, 2026
Jinhai Medical Technology Limited reported a sharp rise in revenue to S$34.0 million for the six months ended 30 June 2026, more than doubling from S$14.5 million a year earlier, driven by improved business performance. Despite higher cost of sale...
Jinhai Medical Technology Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 4, 2026
Jinhai Medical Technology Limited has scheduled a board meeting for 27 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider the declaration of an interim dividend, indi...
Jinhai Medical Appoints Veteran CMO to Drive Minimally Invasive Growth
Aug 3, 2026
Jinhai Medical Technology Limited has appointed industry veteran Ma Chengdong as its chief marketing officer, effective 3 August 2026 for an initial one-year term, tasking him with leading marketing strategy, market access, academic promotion, sal...
Jinhai Medical Wins Strong Shareholder Backing at 2026 AGM
Jun 15, 2026
Jinhai Medical Technology Limited reported that all resolutions proposed at its annual general meeting held on 15 June 2026 were duly passed by shareholders via poll. The meeting covered the adoption of the 2025 audited financial statements, re-el...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 10, 2026